The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands
Abstract
Unstable or harmful agents, such as drugs, vitamins, flavors, pheromones, and catalysts, for use in pharmaceutics, personal care, functional foods, crop protection, laboratories, offices, and industrial processes, require stabilization against oxidation and degradation or shielding from sensitive environments. Therefore, binding them to carriers with high affinity and selectivity for targeting to the right environment and subsequent controlled release is beneficial, especially if this allows improved control of (stimulus-induced) release. Proteins often possess one or more of these properties, whereas modern biotechnology and bioinformatics provide an increasing number of tools to engineer and adapt these properties. Carrier systems are now developed that incorporate proteins as the central ligand-binding component, e.g., lectins for glucose-triggered release of glycosylated insulin and bispecific antibodies for brain targeting of drugs, but ligand-binding proteins can potentially be used in many other applications. Collectively, the proteins available in nature bind an impressive variety of ligands and non-natural analogs. In this light, various ligand-binding protein classes are surveyed, including biotin-, lipid-, immunosuppressant-, insect pheromone-, phosphate-, and sulfate-binding proteins, as well as bacterial periplasmic proteins, lectins, serum albumins, immunoglobulins, and inactivated enzymes. Disadvantages, such as enzymatic degradation or immunogenicity, associated with the pharmaceutical use of certain proteins can be avoided by incorporating these proteins in more complex carrier and targeting systems. In other applications, this may not be necessary. The enclosure of high-affinity (potentially stimulus-sensitive) binding proteins within an envelope that acts as a diffusion barrier for the ligand may provide excellent slow release. Many possibilities seem to be as yet unexplored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands
Schreiber, S. L. (1991) · Science · doi:10.1126/science.1702904 · Cited by 1,494
Crystallographic Studies on a Family of Cellular Lipophilic Transport Proteins
Cowan, S. W., Newcomer, M. E., & Jones, T. A. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1238 · Cited by 180
Cited by
Interaction of β-Lactoglobulin with Resveratrol and its Biological Implications
Liang, L., Tajmir-Riahi, H. A., & Subirade, M. (2008) · Biomacromolecules · doi:10.1021/bm700728k · Cited by 472
Computational design of ligand-binding proteins with high affinity and selectivity
Tinberg, C. E., Khare, S. D., Dou, J., Doyle, L., Nelson, J. W., Schena, A., Jankowski, W., Kalodimos, C. G., Johnsson, K., Stoddard, B. L., et al. (2013) · Nature · doi:10.1038/nature12443 · Cited by 431
Metadata
- Authors
- de Wolf, F. A., & Brett, G. M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2000-06
- Volume
- 52
- Issue
- 2
- Pages
- 207-236
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2138236555
- Cited by
- 186
- References
- 2
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands. https://app.cochat.ai/papers/10.1016/s0031-6997(24)01447-9
- The paper
- de Wolf, F. A., & Brett, G. M. (2000). Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands. Pharmacological Reviews. https://doi.org/10.1016/s0031-6997(24)01447-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.